vs

Side-by-side financial comparison of NEKTAR THERAPEUTICS (NKTR) and Rhinebeck Bancorp, Inc. (RBKB). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $13.5M, roughly 1.6× Rhinebeck Bancorp, Inc.). Rhinebeck Bancorp, Inc. runs the higher net margin — 17.3% vs -165.4%, a 182.7% gap on every dollar of revenue. On growth, Rhinebeck Bancorp, Inc. posted the faster year-over-year revenue change (1701.1% vs -25.3%). Rhinebeck Bancorp, Inc. produced more free cash flow last quarter ($10.9M vs $-65.0M). Over the past eight quarters, Rhinebeck Bancorp, Inc.'s revenue compounded faster (14.0% CAGR vs 0.4%).

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

Rhinebeck Bancorp, Inc. is a US regional bank holding company based in New York. It operates Rhinebeck Bank, offering retail and commercial banking services including deposit accounts, loans, mortgages and wealth management, mainly serving consumers and small-to-medium businesses across New York's Hudson Valley region.

NKTR vs RBKB — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.6× larger
NKTR
$21.8M
$13.5M
RBKB
Growing faster (revenue YoY)
RBKB
RBKB
+1726.3% gap
RBKB
1701.1%
-25.3%
NKTR
Higher net margin
RBKB
RBKB
182.7% more per $
RBKB
17.3%
-165.4%
NKTR
More free cash flow
RBKB
RBKB
$75.9M more FCF
RBKB
$10.9M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
RBKB
RBKB
Annualised
RBKB
14.0%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NKTR
NKTR
RBKB
RBKB
Revenue
$21.8M
$13.5M
Net Profit
$-36.1M
$2.3M
Gross Margin
Operating Margin
-126.9%
21.7%
Net Margin
-165.4%
17.3%
Revenue YoY
-25.3%
1701.1%
Net Profit YoY
-596.9%
188.0%
EPS (diluted)
$-4.67
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NKTR
NKTR
RBKB
RBKB
Q4 25
$21.8M
$13.5M
Q3 25
$11.8M
$14.0M
Q2 25
$11.2M
$13.1M
Q1 25
$10.5M
$12.8M
Q4 24
$29.2M
$750.0K
Q3 24
$24.1M
$773.0K
Q2 24
$23.5M
$10.7M
Q1 24
$21.6M
$10.4M
Net Profit
NKTR
NKTR
RBKB
RBKB
Q4 25
$-36.1M
$2.3M
Q3 25
$-35.5M
$2.7M
Q2 25
$-41.6M
$2.7M
Q1 25
$-50.9M
$2.3M
Q4 24
$7.3M
$-2.7M
Q3 24
$-37.1M
$-8.1M
Q2 24
$-52.4M
$975.0K
Q1 24
$-36.8M
$1.1M
Gross Margin
NKTR
NKTR
RBKB
RBKB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
NKTR
NKTR
RBKB
RBKB
Q4 25
-126.9%
21.7%
Q3 25
-268.6%
23.9%
Q2 25
-324.2%
26.6%
Q1 25
-425.8%
22.9%
Q4 24
49.2%
-444.9%
Q3 24
-142.4%
-1332.3%
Q2 24
-211.9%
11.8%
Q1 24
-163.7%
13.9%
Net Margin
NKTR
NKTR
RBKB
RBKB
Q4 25
-165.4%
17.3%
Q3 25
-301.3%
19.3%
Q2 25
-372.2%
20.8%
Q1 25
-486.4%
17.9%
Q4 24
24.9%
-353.9%
Q3 24
-153.6%
-1042.9%
Q2 24
-222.9%
9.2%
Q1 24
-170.1%
10.8%
EPS (diluted)
NKTR
NKTR
RBKB
RBKB
Q4 25
$-4.67
$0.21
Q3 25
$-1.87
$0.25
Q2 25
$-2.95
$0.25
Q1 25
$-0.24
$0.21
Q4 24
$-2.07
$-0.24
Q3 24
$-2.66
$-0.75
Q2 24
$-3.76
$0.09
Q1 24
$-0.19
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NKTR
NKTR
RBKB
RBKB
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$89.8M
$136.9M
Total Assets
$280.4M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NKTR
NKTR
RBKB
RBKB
Q4 25
$15.1M
Q3 25
$41.0M
Q2 25
$43.0M
Q1 25
$38.9M
Q4 24
$44.3M
Q3 24
$30.1M
Q2 24
$27.9M
Q1 24
$48.6M
Stockholders' Equity
NKTR
NKTR
RBKB
RBKB
Q4 25
$89.8M
$136.9M
Q3 25
$85.1M
$133.0M
Q2 25
$-24.2M
$129.0M
Q1 25
$13.7M
$126.0M
Q4 24
$60.7M
$121.8M
Q3 24
$48.9M
$122.7M
Q2 24
$79.7M
$116.2M
Q1 24
$126.7M
$114.3M
Total Assets
NKTR
NKTR
RBKB
RBKB
Q4 25
$280.4M
$1.3B
Q3 25
$301.3M
$1.3B
Q2 25
$207.5M
$1.3B
Q1 25
$256.2M
$1.3B
Q4 24
$303.9M
$1.3B
Q3 24
$308.0M
$1.3B
Q2 24
$343.3M
$1.3B
Q1 24
$396.0M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NKTR
NKTR
RBKB
RBKB
Operating Cash FlowLast quarter
$-65.0M
$11.7M
Free Cash FlowOCF − Capex
$-65.0M
$10.9M
FCF MarginFCF / Revenue
-298.0%
80.6%
Capex IntensityCapex / Revenue
0.1%
6.3%
Cash ConversionOCF / Net Profit
5.03×
TTM Free Cash FlowTrailing 4 quarters
$-208.7M
$19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NKTR
NKTR
RBKB
RBKB
Q4 25
$-65.0M
$11.7M
Q3 25
$-48.8M
$2.2M
Q2 25
$-45.7M
$2.4M
Q1 25
$-49.1M
$4.3M
Q4 24
$-46.2M
$8.5M
Q3 24
$-43.9M
$-3.6M
Q2 24
$-37.7M
$12.0M
Q1 24
$-47.9M
$-3.5M
Free Cash Flow
NKTR
NKTR
RBKB
RBKB
Q4 25
$-65.0M
$10.9M
Q3 25
$-48.9M
$2.0M
Q2 25
$-45.8M
$2.2M
Q1 25
$-49.1M
$4.2M
Q4 24
$-46.6M
$7.7M
Q3 24
$-44.6M
$-3.6M
Q2 24
$-37.9M
$11.8M
Q1 24
$-48.0M
$-3.7M
FCF Margin
NKTR
NKTR
RBKB
RBKB
Q4 25
-298.0%
80.6%
Q3 25
-414.5%
14.5%
Q2 25
-409.6%
17.2%
Q1 25
-469.0%
32.8%
Q4 24
-159.9%
1023.9%
Q3 24
-184.9%
-469.0%
Q2 24
-161.3%
111.1%
Q1 24
-222.0%
-36.0%
Capex Intensity
NKTR
NKTR
RBKB
RBKB
Q4 25
0.1%
6.3%
Q3 25
1.0%
1.4%
Q2 25
0.3%
1.4%
Q1 25
0.0%
0.9%
Q4 24
1.6%
105.5%
Q3 24
2.8%
6.3%
Q2 24
0.8%
1.2%
Q1 24
0.7%
2.3%
Cash Conversion
NKTR
NKTR
RBKB
RBKB
Q4 25
5.03×
Q3 25
0.83×
Q2 25
0.89×
Q1 25
1.89×
Q4 24
-6.36×
Q3 24
Q2 24
12.27×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons